BPC-157 + TB-500 ("Wolverine") Research Blends: Catalog Overview

Key takeaways

• A BPC-157 + TB-500 blend (informally tagged a "wolverine peptide blend" in the research market) is a single lyophilized vial co-formulated from two distinct research peptides, not a new compound.
• The two constituents are structurally unrelated: BPC-157 is a short 15-residue synthetic peptide, while TB-500 is a longer fragment associated with the 43-residue actin-binding protein Thymosin Beta-4.
• Because a blend mixes two molecules at a stated ratio, the only way to confirm both the identity and the relative amounts is batch documentation — a single product name cannot encode that.
• Blends ship as a white lyophilized powder requiring reconstitution with bacteriostatic water; the combined milligram total is split across the two peptides per the labeled ratio.
• Every Ascend Bio Labs batch — single peptides and blends alike — carries a per-batch Certificate of Analysis with independent third-party HPLC (purity) and LC-MS (identity) data, linked to a unique batch ID on each vial, all US-domestic.

Co-formulated "tissue peptide" blends — most commonly BPC-157 paired with TB-500, sometimes marketed under the informal nickname "wolverine peptide blend" — have become a recognizable category in the research-peptide market. Rather than a single molecule, these are two separate research peptides freeze-dried together into one vial at a stated ratio. This overview treats the blend the way a catalog should: as a category defined by its composition, not by any claimed effect.

Everything below stays strictly within research framing. It describes what is physically in a combined vial — the two constituent peptides, their distinct structures and classes, how a blend is reconstituted and stored, and why batch-level documentation is more important for a mixture than for a single compound. It makes no claims about what either peptide does in any organism. These materials are sold for in-vitro and laboratory research use only.

What a co-formulated blend is — and is not

A BPC-157 + TB-500 blend is a physical mixture: two independently synthesized peptides combined into one vial and lyophilized together. It is not a conjugate, a fusion peptide, or a single new chemical entity. Each molecule retains its own sequence, molecular weight, and chromatographic signature inside the vial. When the blend is analyzed, a clean characterization should resolve both peptides separately, not as one merged species.

The nickname "wolverine peptide blend" is purely a research-market label — a colloquialism, not a chemical or regulatory identifier. Like the names BPC-157 and TB-500 themselves, it tells you nothing verifiable about the contents on its own. That is the central reason a catalog should describe these products by composition and documentation rather than by branding.

Because the category exists only as a pairing of two known peptides, the most useful starting point is understanding each constituent individually. See What Is BPC-157? Peptide Class, Sequence, and Reconstitution and What Is TB-500? Thymosin Beta-4 Fragment Structure and Specs for the single-compound structural detail this overview summarizes.

The two constituents, side by side

What makes this blend notable structurally is that its two components are unrelated molecules from different peptide families. They are not variants of one another; they simply co-occur in the same vial. Reading them side by side makes clear why a mixture needs more documentation than a single peptide, not less.

• BPC-157: a synthetic peptide derived from a partial sequence associated with a gastric protein; a short linear chain of 15 amino acids, supplied as a lyophilized powder.
• TB-500: a synthetic peptide commonly described as a fragment associated with the actin-binding region of Thymosin Beta-4 (Tβ4), a 43-residue protein in the beta-thymosin family.
• Different classes: the two belong to distinct structural families and share no parent molecule — the pairing is a formulation choice, not a biochemical relationship.
• Different sizes: BPC-157 is a short 15-mer; the TB-500 fragment is substantially larger, which is why the two resolve as separate peaks under chromatographic analysis.
• Shared physical form: both arrive as white-to-off-white lyophilized solids and are water-soluble for in-vitro reconstitution.

Ratios, totals, and what the milligram figure means

The most common point of confusion with any blend is the milligram figure on the label. A vial advertised as a 10 mg blend does not contain 10 mg of each peptide — the total is divided between the two constituents at the stated ratio. A 1:1 blend labeled 10 mg, for example, would nominally hold 5 mg of BPC-157 and 5 mg of TB-500; a 2:1 blend would split that total differently. The ratio is therefore as much a part of the product specification as the total mass.

This matters because the ratio and the per-peptide amounts cannot be inferred from the product name alone. Two vials both labeled "BPC-157 + TB-500 10 mg" can contain entirely different per-peptide quantities if their ratios differ. The only authoritative source for what is actually in the vial — both identity of each peptide and, where reported, the relative composition — is the batch documentation, not the SKU.

For a deeper walkthrough of how a single combined vial is composed and characterized, see BPC-157 + TB-500 Blend: What the Combined Vial Contains.

Reconstitution and storage for a two-peptide vial

Handling a blend follows the same lyophilized-peptide workflow as a single compound, with one extra consideration: the reconstitution math is done against the combined contents, and the resulting concentration of each peptide is set by both the total mass and the ratio. The diluent — typically bacteriostatic water — is added slowly down the side of the vial and the vial is gently swirled rather than shaken, since mechanical agitation and foaming can degrade peptides.

Storage requirements do not change because there are two molecules instead of one. The lyophilized powder is the more stable form and is generally kept sealed, cold, and away from light and moisture. Once reconstituted, the solution is less stable, is typically refrigerated, and is used within a limited window while avoiding repeated freeze-thaw cycles. The blend should always be handled per its own batch-specific notes rather than assumptions carried over from a single-peptide product.

• Reconstitute against the combined mass; per-peptide concentration depends on both total mg and the labeled ratio.
• Add diluent slowly down the vial wall and swirl gently — never shake — to avoid foaming and degradation.
• Lyophilized blend: store sealed, cold, away from light and humidity — the most stable holding form.
• Reconstituted blend: refrigerate (typically 2–8°C), use within a limited window, avoid freeze-thaw cycling.
• Confirm storage and ratio details against the per-batch Certificate of Analysis for the exact lot.

Why blends raise the documentation bar

For a single peptide, a Certificate of Analysis confirms one identity and one purity figure. A blend doubles the surface area for error: a buyer needs confidence that both peptides are present, that each is the molecule claimed, and that neither is degraded or substituted. A mixture is also a place where under-dosing one constituent is harder to notice without analysis, because the powder looks identical regardless of the internal ratio.

That is why per-batch, lot-linked documentation is the practical differentiator for this category. Independent HPLC characterizes purity and should resolve the constituents as distinct peaks, while LC-MS confirms each peptide's molecular identity by observed mass. When those reports are published per batch and tied to a unique ID on the vial, a researcher can verify the specific lot in hand rather than trusting a generic spec sheet. The table below frames what to look for when comparing how vendors document a blend — using only attributes each vendor publicly states.

For a like-for-like documentation comparison on this exact product category, see Ascend Bio Labs vs Cosmic Peptides for BPC-157 + TB-500 Blend: Documentation Compared.

Where blends sit in the catalog

Within the Ascend Bio Labs catalog, co-formulated blends sit alongside the single-compound listings rather than replacing them. A researcher who wants to characterize one peptide in isolation buys the single SKU; a researcher working with a combined preparation buys the blend. Both routes carry the same documentation standard, so the choice is about the experimental material needed, not about which product is better verified.

Treating blends as a defined catalog category — rather than an afterthought bundle — also keeps the labeling honest. Each blend listing should state its two constituents and ratio, and each should resolve to its own per-batch COA. That is the structural commitment behind this category: a blend is two documented peptides in one vial, and the documentation is what makes the pairing meaningful.

Every product referenced here, single or blended, is sold strictly as a research material for in-vitro and laboratory use only — not for human or veterinary use.

Related research notes

• BPC-157 + TB-500 Blend: What the Combined Vial Contains
• What Is BPC-157? Peptide Class, Sequence, and Reconstitution
• What Is TB-500? Thymosin Beta-4 Fragment Structure and Specs
• Ascend Bio Labs vs Cosmic Peptides for BPC-157 + TB-500 Blend: Documentation Compared